1. Scrip
  2. >>Business
  3. >>Earnings

Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism

 
• By Joseph Haas

Sales of the Bristol PD-1 inhibitor dropped 9% year-over-year but the company says approvals in first-line NSCLC are off to a good start. Q2 saw growth for Eliquis and Revlimid despite pandemic impact.

Bristol-Myers-Squib_685347493_1200.jpg
Bristol sees positive early trends for the Opdivo/Yervoy combo in first-line lung cancer

Bristol-Myers Squibb Company execs talked up Opdivo’s growth prospects moving forward on the company’s second quarter earnings call on 6 August, saying that launch of the PD-1 inhibitor in combination with its CTLA-4 inhibitor Yervoy (ipilimumab) in first-line non-small cell lung cancer is off to a good start and that renal cell carcinoma could offer another growth area for the immuno-oncology agent.

There have been concerns about Opdivo (nivolumab) given continued strong growth for Merck & Co., Inc.’s best-selling PD-1 rival Keytruda (pembrolizumab), which has meant sluggish sales for Bristol’s drug. (Also see "BMS Sales Surged In Q1 Even Without Big COVID-19 Boost" - Scrip, 8 May, 2020.) During the second quarter, Opdivo yielded $1.65bn in sales, down 9% year-over-year as well as a 6% decline from the first quarter of 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.